BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Medicure Inc. MCUJF
10 fiscal years on record · CAD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
CAD 21.9M
▲ 1.0% vs FY2023
EPS · FY24
CAD -0.10
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
—
Net margin · FY24
-4.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
CAD 21.9M
Revenue, FY2024 · full 10-year series below
Revenue
Net income
The company lost 5 cents on every revenue dollar this year.
Per share
CAD -0.10
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2024
ROE
Operating margin—
Net margin-4.7%
Return on assets-3.6%
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+1.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+0.2%
+1.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
CAD 29.7M
total assets, end of FY2024
Total assetsCAD 29.7M
CashCAD 7.2M
Current ratio1.89×
History
10 fiscal years
Every figure from documents filed with the SEC · CAD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue CAD B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income CAD B
·
·
·
·
·
·
−0.0
0.0
0.0
0.0
EBITDA CAD B
·
·
·
·
·
·
−0.0
0.0
·
·
Income tax CAD B
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
Net income CAD B
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
EPS, diluted CAD
−0.10
−0.09
0.13
−0.07
−0.64
−1.32
0.24
2.39
1.56
0.11
Dividend / sh CAD
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
4.9
74.3
74.6
·
Shares out B
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
38 of 38
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed